Patient group has 'grave concern' about New Zealand's Therapeutic Products Bill

21 March 2023
new-zealand

Patient Voice Aotearoa’s Dr Malcolm Mulholland appeared before the Health Select Committee to voice opposition to parts of the Therapeutic Products Bill on behalf of  patients in New Zealand.

“The Bill threatens to obstruct access to unfunded medicines by making it illegal for New Zealanders to import prescription medicines via post” says Dr Mulholland, adding: “We are aware of countless Kiwis who have turned to importing medicines to save their lives. The Therapeutic Products Bill in its current form would be a death sentence for these patients.”

Patient Voice Aotearoa is also gravely concerned about the Bill creating a barrier to clinical trials, and making it illegal for patients, advocates, doctors, and media from publicly discussing the need to fund unfunded medicines.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical